Table 1 Major baseline characteristics.
From: Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study
Characteristics | All patients (N = 42) | Vardenafil (N = 21) | Placebo (N = 21) |
|---|---|---|---|
Gender | |||
Male | 30 (71%) | 14 (67%) | 16 (76%) |
Female | 12 (29%) | 7 (33%) | 5 (24%) |
Age, years (mean ± SD) | 49.0 ± 10.2 | 51.3 ± 10.0 | 46.7 ± 10.2 |
Body weight, kg (mean ± SD) | 81.6 ± 17.0 | 82.6 ± 19.2 | 80.6 ± 14.8 |
BMI, kg/m2 (mean ± SD) | 26.5 ± 3.9 | 27.1 ± 4.2 | 25.9 ± 3.5 |
Non-smokers | 27 (64%) | 16 (76%) | 11 (52%) |
Smokers | 15 (36%) | 5 (24%) | 10 (48%) |
Pack-year historya (mean ± SD) | 17.3 ± 10.8 | 19.9 ± 10.7 | 15.9 ± 11.3 |
Current alcohol consumption | |||
Abstinent | 15 (36%) | 8 (38%) | 7 (33%) |
Light/moderate (≤ 2 unitsb per day) | 27 (64%) | 13 (62%) | 14 (67%) |
Tinnitus duration, years (mean ± SD) | 6 ± 5 | 7 ± 6 | 5 ± 3 |
Course of tinnitus | |||
Constant | 30 (71%) | 17 (81%) | 13 (62%) |
Progressive | 12 (29%) | 4 (19%) | 8 (38%) |
Tinnitus prevalence | |||
Ears without tinnitus | 17 (20%) | 9 (21%) | 8 (19%) |
Ears with tinnitus | 67 (80%) | 33 (79%) | 34 (81%) |
Tonal type | 60 (90%) | 29 (88%) | 30 (88%) |
Noise type | 7 (10%) | 4 (12%) | 4 (12%) |
Hearing level in tinnitus earsc | |||
Normacusis (<20 dB) | 8 (12%) | 0 (0%) | 8 (23%) |
Mild hearing loss (20–40 dB) | 49 (73%) | 28 (85%) | 21 (62%) |
Moderate hearing loss (41–60 dB) | 9 (14%) | 4 (12%) | 5 (15%) |
Severe hearing loss (>60 dB) | 1 (1%) | 1 (3%) | 0 (0%) |
Tinnitus annoyance | |||
cT (TQ total score ≤ 46) | 27 (64%) | 13 (62%) | 14 (67%) |
dT (TQ total score ≥ 47) | 15 (36%) | 8 (38%) | 7 (33%) |